
CNS Solutions
Gain expert clinical guidance and improved data quality to support your CNS clinical studies
Gain expert clinical guidance and improved data quality to support your CNS clinical studies
The WCG CNS Group combines the scientific and clinical expertise of VeraSci, MedAvante-ProPhase, and Analgesic Solutions, three leaders in delivering true outcomes for some of the most subjective and complex indications, including psychiatric, neurodegenerative, and pain clinical trials.
Our neuroscience leaders have helped sponsors and CROs reduce the risk of trial failure by supporting the science, data integrity, and approval of vital CNS therapies. From our purpose-built CNS technology to our ability to support global operations with scientific oversight, we have brought together world-renown minds to help you carry out confident decision-making in CNS drug development.
reduction in error rates for endpoints
for deployment of patient assessments
gold-standard certified raters at a global scale
Sponsors and CROs continue to face extreme challenges and high risks in the design and execution of clinical trials in support of new CNS therapies. The likelihood of a clinical success is narrow, and the variability of data generated in the study only exacerbates the challenges.
Beyond the challenges in trial design, the identification and training of sites in the execution of CNS studies have grown even more complex. With the need to ensure the right scales, technologies and reviews are in place to ensure the data is high-quality and analyzed appropriately.
Our CNS solution is a modular suite of services that apply the widely-acknowledged clinical expertise of WCG scientists and clinicians to mitigate the risks of bias, variability, and human error, while addressing the root causes of failed and inconclusive CNS trials.
WCG’s evidence-based solution integrates clinical expertise and specialized technology in a targeted solution, reducing error rates for clinical endpoints by up to 85% through effective training and best practice implementation with eCOA.
Chief Executive Officer
WCG VeraSci
VP, Regulatory Strategy and Market Access Innovation
WCG VeraSci
Chief Scientific Officer
WCG MedAvante-ProPhase
Senior Director, Psychological Assessments
WCG VeraSci
Therapeutic Focus:
Childhood Disorders; Rare & Orphan Diseases
VP, Scientific Development
WCG VeraSci
Senior Clinical Director, Movement Disorders
WCG VeraSci
Therapeutic Focus:
Parkinson’s Disease
VP, Clinical Scientist
WCG VeraSci
Therapeutic Focus:
Schizophrenia
Chief Research Officer
WCG MedAvante-ProPhase
VP, Scientific Operations
WCG VeraSci
Chief Scientific Officer
WCG Analgesic Solutions
Senior Medical Scientist
WCG VeraSci
Therapeutic Focus:
Multiple Sclerosis
VP, Clinical Science
WCG VeraSci
VP, Neurodegenerative Disorders
WCG VeraSci
Therapeutic Focus:
Alzheimer’s Disease
Senior Scientific Expert, Neurodevelopment Disorders
WCG MedAvante-ProPhase
A short conversation should help assess your need and how WCG can assist. To arrange a call with one of our CNS experts, simply fill out this form.